profit from every $100 of sales.
$0$100
Charles River Laboratories International
$337.97-0.83% today
+99.7% in 1 year
1-year low $149.931-year high $376.10
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Charles River Laboratories International sold, what it kept, and what it did with the cash.
Sales went from $3.98 billion in 2022 to $4.02 billion in 2025, with -$144 million of profit last year.
SalesProfit
Charles River Laboratories International handed back 70% of the cash it generated last year.
Buybacks $361M
Free cash flow 2025$518M
Bought back its own shares$361M
Paid as dividends–
Cash vs. debt$214M vs. $2.6B
Charles River Laboratories International vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Charles River Laboratories International | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Charles River Laboratories International's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,924 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | |
| – | – | 1,463 | 1,503 | 1,332 | 1,323 | |
| – | – | 651 | 617 | 442 | 401 | |
| 768 | 820 | 986 | 1,032 | 581 | 411 | |
| 364 | 391 | 486 | 475 | 10 | -144 | |
| 7.20 | 7.60 | 9.48 | 9.22 | 0.20 | -2.91 | |
| – | – | 36.8% | 36.4% | 32.9% | 33.0% | |
| – | – | 16.4% | 14.9% | 10.9% | 10.0% | |
| 12.5% | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 5,491 | 7,024 | 7,603 | 8,195 | 7,528 | 7,135 |
| Cash | 228 | 241 | 234 | 277 | 195 | 214 |
| Total debt | 2,157 | 2,950 | 3,097 | 3,066 | 2,724 | 2,628 |
| Total liabilities | 3,347 | 4,432 | 4,579 | 4,536 | 4,020 | 3,924 |
| 2,115 | 2,535 | 2,976 | 3,597 | 3,462 | 3,165 | |
| 51 | 51 | 51 | 51 | 52 | 50 | |
| 9.9% | 8.0% | 8.9% | 8.5% | 2.8% | 0.1% | |
| 17.2% | 15.4% | 16.3% | 13.2% | 0.3% | -4.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 547 | 761 | 620 | 684 | 735 | 738 | |
| 167 | 229 | 325 | 319 | 233 | 219 | |
| 380 | 532 | 295 | 365 | 502 | 518 | |
| Dividends paid | – | – | – | – | – | – |
| 24 | 41 | 39 | 24 | 119 | 361 | |
| 56 | 71 | 74 | 72 | 70 | 71 |
Valuation
- –
- 30.5×
- –
- 2.5×
- 4.0×
- 31.2×
- 45.3×
- 3.2%
- -0.9%
- 0.0%
Profitability
- 33.0%
- 10.0%
- -3.6%
- 20.0%
- 7.1%
- 4.0%
- -5.7%
- -2.4%
- 7.1%
- –
Growth
- +6.5%
- –
- +3.4%
- –
- −0.4%
Financial health
- 3.6×
- 1.04
- 39.5%
- 4.5×
- 1.36
- 1.03
- 0.52
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 42%of 946
Top 48%of 872
Bottom 33%of 868
Top 33%of 986
What analysts expect
- Average price target
- $205.43
- Range
- $175.00 – $260.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 2.06 | 1.96 | +5.1% |
| Feb 18, 2026 | 2.39 | 2.33 | +2.6% |
| Nov 5, 2025 | 2.43 | 2.32 | +4.7% |
| Aug 6, 2025 | 3.12 | 2.50 | +24.8% |
| May 7, 2025 | 2.34 | 2.06 | +13.6% |
| Feb 19, 2025 | 2.66 | 2.50 | +6.4% |
| Nov 6, 2024 | 2.59 | 2.42 | +7.0% |
| Aug 7, 2024 | 2.80 | 2.39 | +17.2% |
News
Charles Schwab and DoorDash ranked among bargain stocks that could lead the market higherMarketWatch · Oct 14, 2026Charles River Labs and Autolomous launch Apollo Orchestrate for digital lab executionSeeking Alpha · Oct 6, 2026Charles Schwab takes huge gamble on single stock futuresYahoo Finance · Aug 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
26No pass
Philip Fisher
26No pass
Peter Lynch
32No pass
Joel Greenblatt
3No pass
Charlie Munger
17No pass
Terry Smith
14No pass
Questions about Charles River Laboratories International
Is Charles River Laboratories International a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Charles River Laboratories International AI analysis
What does Charles River Laboratories International do?
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It is in Medical - Diagnostics & Research, based in Wilmington, MA, United States, with 18,300 employees.
Does Charles River Laboratories International pay a dividend?
No. Charles River Laboratories International does not pay a dividend at the moment; in 2025 it returned $361 million to shareholders by buying back its own shares.
Is Charles River Laboratories International stock halal?
Yes. Charles River Laboratories International passes our halal screen: its business is permitted and its debt is 16% of its market value, under the 30% limit. How we check
How has Charles River Laboratories International stock done over the past year?
Up 99.7% over the past twelve months, to $337.97. It traded between $149.93 and $376.10 and is 10.1% below its high.
Who are Charles River Laboratories International's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Charles River Laboratories International's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.